1.
Zhonghua Wai Ke Za Zhi
; 58(2): 99-104, 2020 Feb 01.
Article
in Chinese
| MEDLINE
| ID: mdl-32074807
ABSTRACT
Pancreatic cancer is malignant and has a poor prognosis.At present, the treatment mode has changed from "Surgery First" to systemic therapy under multi-disciplinary team, but surgical resection is still the only way to cure pancreatic cancer. In systemic treatment of pancreatic cancer, the effect of postoperative adjuvant therapy is significant, and preoperative neoadjuvant therapy has gradually attracted widespread attention. Neoadjuvant therapy can improve the rate of R0 resection in patients with pancreatic cancer.There is a consensus on neoadjuvant therapy for patients who with borderline resectable and locally advanced, but for the patients who with resectable remains controversial.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Neoadjuvant Therapy , Pancreatic Neoplasms , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Consensus , Humans , Neoplasm Staging , Pancreatic Neoplasms/drug therapy
2.
Zhonghua Nei Ke Za Zhi
; 31(8): 484-9, 1992 Aug.
Article
in Chinese
| MEDLINE
| ID: mdl-1304984